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Ireny Y.K. Iskandar1, Richard B. Warren2,3, Mark Lunt4, Kayleigh J. Mason3, Ian Evans3,
Kathleen McElhone3, Catherine H. Smith5, Nick J. Reynolds6,7, Darren M. Ashcroft1,8 and
Christopher E.M. Griffiths2,3,8, on behalf of the BADBIR Study GroupLittle is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice.
We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation
due to adverse events or ineffectiveness in patients with psoriasis who had failed a first biologic therapy and
switched to a second in a large, multicenter pharmacovigilance registry (n ¼ 1,239; adalimumab, n ¼ 538; eta-
nercept, n ¼ 104; ustekinumab, n ¼ 597). The overall drug survival rate in the first year after switching was 77%
(95% confidence interval ¼ 74e79%), falling to 58% (55e61%) in the third year. Female sex, multiple comor-
bidities, concomitant therapy with cyclosporine, and a high Psoriasis Area and Severity Index at switching to the
second-line biologic therapy were predictors of overall discontinuation (multivariable Cox proportional hazard
model). Compared to adalimumab, patients receiving etanercept were more likely to discontinue therapy
(hazard ratio ¼ 1.87, 95% confidence interval ¼ 1.24e2.83), whereas patients receiving ustekinumab were more
likely to persist (hazard ratio ¼ 0.46; 95% confidence interval ¼ 0.33e0.64). Discontinuation of the first biologic
therapy because of adverse events was associated with an increased rate of second drug discontinuation
because of adverse events (hazard ratio ¼ 2.55; 95% confidence interval ¼ 1.50e4.32). In conclusion, drug
survival rates differed among biologic therapies and decreased over time; second-line discontinuation because
of adverse events was more common among those who discontinued first-line treatment for this reason. The
results of this study should support clinical decision making when choosing second-line biologic therapy for
patients with psoriasis.
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Biologic therapies have markedly improved the management
of moderate to severe psoriasis. The efficacy of these thera-
pies has been established in large randomized clinical trials,
with up to 88% of patients achieving at least a 75%
improvement in the Psoriasis Area and Severity Index (PASI)
(Nast et al., 2015; Reich et al., 2012). In addition, several
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Despite these impressive findings, approximately 11e35%
of patients fail their first biologic therapy during the first year
of treatment, either because of ineffectiveness or following
the development of adverse events (AEs) (Warren et al.,
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776common (Iskandar et al., 2017a; Leman and Burden, 2012;
Norlin et al., 2012), with several studies suggesting that
initiating therapy with a second biologic is beneficial
(Clemmensen et al., 2011; Downs, 2010; Gottlieb et al.,
2012; Lecluse et al., 2009; Mazzotta et al., 2009; Ortonne
et al., 2011; Van Lu¨mig et al., 2010). However, to date,
these studies have included relatively small numbers of pa-
tients (range ¼ 10e282 patients), which makes it difficult to
establish a substantive estimate of the risk of recurrent
discontinuation because of AEs or ineffectiveness. Further-
more, the optimal choice of the subsequent treatment in
those patients who fail or who are intolerant of the first-line
biologic treatment is not established (Mauskopf et al., 2014).
Drug survival is a comprehensive measure of drug effec-
tiveness, safety, and real-world utility (van den Reek et al.,
2015a). Several studies reported on drug survival with
biologic therapies among patients previously exposed to
biologic therapies. Four of these studies have reported only
on drug survival with tumor necrosis factor inhibitors (TNFIs)
(Brunasso et al., 2012; Gniadecki et al., 2011; Inzinger et al.,
2016; Menting et al., 2014), two studies involved the Danish
National Psoriasis Biologic Safety Registry Data (Gniadecki
et al., 2011, 2015), one study involved the PSOriasis Longi-
tudinal Assessment and Registry (Menter et al., 2016), and the
other studies reported data from either a single or a limited
number of dermatology centers (Lo´pez-Ferrer et al., 2013;
Umezawa et al., 2013; van den Reek et al., 2015b; van
den Reek et al., 2014a; Zweegers et al., 2016b). The find-
ings from these studies differ markedly; for instance, Menting
et al. (2014) reported that drug survival did not differ signif-
icantly between biologic therapies among patients previously
exposed to biologic therapies, whereas Gniadecki et al.
(2015) found that the survival of ustekinumab was equal to
that of adalimumab and infliximab but superior to that of
etanercept. More recently, Menter et al. (2016) found that
ustekinumab had superior drug survival compared with
infliximab, adalimumab, and etanercept. Moreover, none of
these studies took into consideration that the threshold for
drug discontinuation may change over time (Da´vila-Seijo
et al., 2016) or investigated whether the reason for failing
the first-line biologic therapy is predictive of the clinical
outcome in patients receiving a second biologic therapy.
Furthermore, Menter et al. (2016) included patients who
could have discontinued their previous biologic therapy
before enrollment into the register; this has the potential to
introduce a source of bias due to left censorship.
Therefore, a number of clinically important questions
remain unanswered. First, drug survival with second-line
biologic therapies in routine clinical practice needs further
exploration. In doing so, the effect of the increasing number
of biologic therapies available to treat psoriasis in recent
years and their effect on the threshold for drug discontinua-
tion need to be considered (Da´vila-Seijo et al., 2016). In
addition, the risk of recurrent discontinuation because of AEs
or ineffectiveness and whether the reason for failing a first
biologic therapy is predictive of failure of a second is
unknown and warrants investigation.
The British Association of Dermatologists Biologic
Interventions Register (BADBIR) is a UK and Republic of
Ireland prospective, longitudinal pharmacovigilance register.Journal of Investigative Dermatology (2018), Volume 138This represents an ideal resource to assess real-world drug
survival with second-line biologic therapies for psoriasis
because of its large size, a rigorous data collection process,
inclusion of clinically relevant covariates, and high external
validity through the participation of 153 dermatology centers
(Burden et al., 2012). In this cohort study, we examined the
comparative drug survival with second-line use of adalimu-
mab, etanercept, and ustekinumab and identified clinically
relevant risk factors for drug discontinuation. We also esti-
mated the risk of recurrent discontinuation because of AEs or
ineffectiveness.
RESULTS
From a prospective cohort of 6,109 biologic-naı¨ve patients
with psoriasis, we identified a total of 1,239 (adalimumab,
n ¼ 538; etanercept, n ¼ 104; ustekinumab, n ¼ 597) who
failed their first biologic therapy and were switched to a
second while under follow-up in the BADBIR (Figure 1).
Overall, 1,181 (95%) of these patients failed first-line TNFIs,
and 47 (4%) and 11 (1%) patients failed first-line ustekinu-
mab or other biologic therapies, respectively (see
Supplementary Table S1 online). Patients who failed first-line
TNFIs were switched to second-line ustekinumab (50%),
adalimumab (42%), and etanercept (8%); 89% and 46% of
patients failing first-line ustekinumab and other biologic
therapies were switched to second-line adalimumab and
etanercept, respectively (see Supplementary Table S1). In
total, 941 (76%) of those patients who were switched to
second-line biologic therapies discontinued the first biologic
therapy because of ineffectiveness, whereas 154 (12%) and
144 (12%) patients discontinued the first biologic therapy
because of the development of AEs or for other reasons,
respectively (see Supplementary Table S2 online).
At the time of switching to a second biologic therapy, the
mean  standard deviation age of patients was 46.3  12.8
years, with 42% female. The mean PASI and Dermatology
Life Quality Index were 12.4  9.8 and 13.3  13.7,
respectively. Overall, 285 (23%) patients reported having
psoriatic arthritis (PsA), and 70% reported having one or
more comorbidities other than PsA. Baseline (at the time of
switching) demographic and disease characteristics are
summarized in Table 1.
Drug survival with second-line biologic therapies
Drug survival data for second-line biologic therapies were
available for a mean  standard deviation, total follow-up,
and range of follow-up time of 2.7  1.6; 2,405.7; and
0.5e7.8 person-years, respectively, with a mean  standard
deviation follow-up time for patients receiving adalimumab
of 3.2  1.7 years, those receiving etanercept of 2.7  1.6
years, and those receiving ustekinumab of 2.31.3 years.
Over the time frame of the study, 457 of 1,239 patients (37%)
discontinued their second biologic therapy.
Kaplan-Meier survival analyses (Table 2) found an
overall survival rate of 77% (95% confidence interval
[CI] ¼ 74e79%) one year after switching, falling to 58%
(55e61%) at 3 years. For individual biologic therapies, the
1-year survival rate for ustekinumab was 85% (82e87%), for
adalimumab was 74% (70e77%), and for etanercept was
49% (39e58%), falling to 73% (68e77%), 50% (46e55%),
Figure 1. Patient selection. †Patients with a gap of 90 days or greater after the
start date of the first-line biologic therapy were defined as discontinuing their
first-line biologic therapy and were further classified into one of three
mutually exclusive groups based on the treatment patterns after the first
90-day gap: discontinued, restarted, or switched therapy. *Patients were
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year after starting therapy with second-line biologic thera-
pies, 15% (13e17%) of patients discontinued therapy
because of ineffectiveness, 5% (4e7%) because of AEs, and
3% (2e4%) for other reasons (Table 2). The most common
AEs to cause discontinuation of the second biologic therapy
were infections (2%), nervous system disorders (1%), and
skin and subcutaneous tissue disorders (1%). Supplementary
Figure S1 online shows second-line drug survival for biologic
therapies by discontinuation because of ineffectiveness or
AEs.
A sensitivity analysis investigating the impact of switching
from first-line TNFIs showed similar findings to the overall
patient cohort. The corresponding overall survival rate was
78% (75e80%) 1 year after switching, falling to 59%
(56e63%) at 3 years (see Supplementary Table S3 online). For
individual biologic therapies, the 1-year survival rate for
ustekinumab was 85% (81e87%), for adalimumab was 75%
(71e79%), and for etanercept was 46% (36e56%), falling to
73% (68e77%), 51% (46e56%), and 33% (22e43%),
respectively, at 3 years (see Supplementary Table S3). Other
sensitivity analyses investigating the impact of switching from
first-line etanercept (see Supplementary Table S4 and
Supplementary Figure S2a online) or adalimumab (see
Supplementary Table S5 and Supplementary Figure S2b on-
line) to second-line biologic therapies also found that the
differential overall drug survival with second-line biologic
therapies was similar to the findings for the overall patient
cohort.
Predictors of drug survival with second-line biologic
therapies
Table 3 presents results from the univariable and multivari-
able analyses examining predictors of overall drug discon-
tinuation, discontinuation due to ineffectiveness, and
discontinuation due to AEs.
For overall discontinuation of the second biologic therapy,
the multivariable model showed that being female (hazard
ratio [HR]¼ 1.31, 95% confidence interval [CI]¼ 1.08e1.60),
having multiple comorbidities other than PsA compared with
having no comorbidities (three or four comorbidities:
HR ¼ 1.46, 95% CI ¼ 1.07e1.98; five or more comorbidities:
HR ¼ 1.56, 95% CI ¼ 1.02e2.39), having a higher PASI at the
time of switching to the second biologic therapy (per 1-point
increase in PASI score: HR ¼ 1.02, 95% CI ¼ 1.01e1.04),
concomitantly using cyclosporine with the second biologic
therapy (HR ¼ 1.55, 95% CI ¼ 1.02e2.36), and taking
etanercept rather than adalimumab (HR ¼ 1.87, 95%
CI ¼ 1.24e2.83) were predictors of discontinuation.
In contrast, taking ustekinumab rather than adalimumab
(HR ¼ 0.46, 95% CI ¼ 0.33e0.64) was a predictor for drug
survival (Table 3 and Figure 2b). Furthermore, patients whoclassified as discontinued therapy if they did not receive any biologic therapy
after the first 90-day gap. ** Patients were classified as restarted therapy if they
had a treatment gap that exceeded the 90-day period and subsequently
restarted the same biologic therapy. *** Patients were classified as switched
therapy if they initiated a new biologic therapy after the first 90-day gap
(Iskandar et al., 2017a). ††Includes rituximab, certolizumab, or golimumab.
BADBIR, British Association of Dermatologists Biologic Interventions Register.
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Table 1. Demographic and disease characteristics at the time of switch to second biologic therapy
Characteristics
All Patients1
(n¼ 1239)
Etanercept
(n¼ 104;8.4%)
Adalimumab
(n¼538; 43.4%)
Ustekinumab
(n¼597; 48.2%)
Demographic
Age in years, mean (SD) 46.3 (12.8) 46.8 (12.2) 46.1 (12.7) 46.4 (13.0)
Female, n (%) 515 (41.6) 55 (52.9) 222 (41.3) 238 (39.9)
BMI1, n (%)
Nonobese (<30 kg/m2) 525 (42.4) 41 (39.1) 229 (42.5) 255 (42.8)
Obese (30 kg/m2) 714 (57.6) 63 (60.9) 309 (57.5) 342 (57.2)
Smoking status1,2, n (%)
Never smoked 393 (31.7) 26 (24.5) 190 (35.2) 178 (29.9)
Ex-smoker 404 (32.6) 33 (31.8) 168 (31.3) 203 (34.0)
Current smoker 442 (35.6) 45 (43.7) 180 (33.5) 216 (36.1)
Psoriatic arthritis, n (%) 285 (23.0) 32 (30.8) 130 (24.2) 123 (20.6)
Total number of co-morbidities (excluding PsA)2, n (%)
No comorbidities 369 (29.8) 26 (25.0) 153 (28.4) 190 (31.8)
1e2 comorbidities 591 (47.7) 51 (49.0) 277 (51.5) 263 (44.1)
3e4 comorbidities 210 (17.0) 13 (12.5) 87 (16.2) 110 (18.4)
5 comorbidities 69 (5.6) 14 (13.5) 21 (3.9) 34 (5.7)
Disease, mean (SD)
Disease duration in years1 22.9 (12.7) 22.9 (13.4) 23.3 (12.6) 22.5 (12.7)
Age of onset in years1 23.4 (13.4) 23.9 (12.8) 22.8 (13.2) 23.9 (13.7)
PASI1 12.4 (9.8) 12.9 (9.4) 11.3 (8.8) 13.4 (10.4)
DLQI1 13.3 (13.7) 14.2 (10.8) 12.5 (12.8) 13.9 (13.2)
Medication history, n (%)
Concomitant methotrexate 130 (10.5) 12 (11.5) 63 (11.7) 55 (9.2)
Concomitant cyclosporine 67 (5.4) 4 (3.8) 26 (4.8) 37 (6.2)
Concomitant other systemics3 33 (2.7) <5 (1.0) 16 (3.0) 16 (2.7)
Abbreviations: BMI, body mass index; DLQI, dermatology life quality index; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SD, standard
deviation.
1A multiple imputation model of 80 cycles was performed to account for missing data.
2Collected only at the time of registration.
3Includes any of acitretin, fumaric acid esters, hydroxcarbamide, azathioprine, and mycophenolate mofetil.
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778discontinued their first biologic therapy because of develop-
ment of an AE were associated with significantly higher overall
discontinuation rates of the second biologic therapy compared
with patients who discontinued their first biologic therapy
because of ineffectiveness (HR ¼ 1.34, 95% CI ¼ 1.01e1.78).
For discontinuation of the second biologic therapy because
of ineffectiveness, concomitantly using cyclosporine with the
second biologic therapy (HR ¼ 2.17, 95% CI ¼ 1.28e3.68)
and taking etanercept rather than adalimumab (HR ¼ 2.44,
95% CI ¼ 1.40e4.25) were predictors of discontinuation,
whereas taking ustekinumab rather than adalimumab (HR ¼
0.41, 95% CI ¼ 0.26e0.64) was a predictor for drug survival.
There was no significantly increased risk of drug discontin-
uation because of ineffectiveness in those patients who dis-
continued their first biologic therapy for this reason (HR ¼
1.04, 95% CI ¼ 0.69e1.56).
For discontinuation of the second biologic therapy because
of AEs, female sex (HR ¼ 1.53, 95% CI ¼ 1.01e2.32), the
presence of multiple comorbidities other than PsA compared
with having no comorbidities (three or four comorbidities:
HR ¼ 1.95, 95% CI ¼ 1.02e3.73), and having other biologic
therapies (such as efalizumab and clinical trial biologic
therapies) rather than etanercept as first-line biologic thera-
pies (HR ¼ 4.62, 95% CI ¼ 1.28e16.62) were predictors of
discontinuation, whereas having a longer disease duration at
the time of switching to the second biologic therapyJournal of Investigative Dermatology (2018), Volume 138(per 10 years increase in disease duration: HR ¼ 0.79, 95%
CI ¼ 0.66e0.95), concomitantly using methotrexate with the
second biologic therapy (HR ¼ 0.29, 95% CI ¼ 0.11e0.81),
and taking ustekinumab rather than adalimumab (HR ¼ 0.38,
95% CI ¼ 0.18e0.77) were predictors for drug survival. First
drug discontinuation due to AEs was associated with an
increased rate of second drug discontinuation due to this
reason (HR ¼ 2.55, 95% CI ¼ 1.50e4.32). However, only
three patients experienced the same AE during therapy with
the first and second biologic courses (skin and subcutaneous
tissue disorder, n ¼ 1; infections, n ¼ 2).
DISCUSSION
In this large prospective cohort study, we found that after
failure of a first-line biologic therapy, most patients with
psoriasis who were switched to a second biologic therapy
continued with this therapy for an estimated 1-year drug
survival rate of 77%. This is similar to the estimated 1-year
drug survival rates of first-line biologic therapies, which we
have reported on previously (Warren et al., 2015). One of the
most notable findings was that the likelihood of patients
experiencing an AE with the second agent was increased
approximately 2.5-fold if the first agent was also stopped
because of an AE, although recurrence of the same AE was
rare. The mechanisms that may underlie this require further
investigation.
Table 2. The overall and differential second-line biologic survival functions, stratified by reason for drug
discontinuation, at years 1, 2 and 31
Reasons for Drug
Discontinuation Second Biologic (n [ 1,239) Adalimumab (n [ 538) Etanercept (n [ 104) Ustekinumab (n [ 597)
All reasons
Year 1 0.77 (0.74e0.79) 0.74 (0.70e0.77) 0.49 (0.39e0.58) 0.85 (0.82e0.87)
Year 2 0.65 (0.62e0.68) 0.59 (0.54e0.63) 0.36 (0.26e0.46) 0.77 (0.73e0.80)
Year 3 0.58 (0.55e0.61) 0.50 (0.46e0.55) 0.25 (0.14e0.37) 0.73 (0.68e0.77)
Ineffectiveness
Year 1 0.85 (0.83e0.87) 0.84 (0.80e0.87) 0.58 (0.47e0.68) 0.91 (0.88e0.93)
Year 2 0.78 (0.75e0.81) 0.74 (0.70e0.78) 0.47 (0.36e0.58) 0.87 (0.84e0.90)
Year 3 0.75 (0.72e0.78) 0.71 (0.66e0.75) 0.38 (0.23e0.53) 0.85 (0.81e0.88)
Adverse events
Year 1 0.95 (0.93e0.96) 0.94 (0.91e0.95) 0.87 (0.78e0.92) 0.97 (0.95e0.98)
Year 2 0.92 (0.90e0.94) 0.91 (0.87e0.93) 0.85 (0.75e0.91) 0.95 (0.92e0.97)
Year 3 0.89 (0.86e0.91) 0.85 (0.81e0.89) 0.73 (0.51e0.86) 0.94 (0.92e0.96)
1Data presented as mean (95% confidence interval).
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predictor for discontinuation overall and due to ineffective-
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Figure 2. Crude and adjusted drug survival curves of the second biologic
course. (a) Crude drug survival of the second biologic course showing
disaggregated biologic data (Kaplan-Meier survival curve). (b) Adjusted drug
survival curves using disaggregated data based on the overall multivariable
Cox proportional hazard model in Table 3.survival. This difference persisted after adjustment for
important clinical factors likely to influence treatment
response. Other important predictors for drug discontinua-
tion included female sex, multiple comorbidities, a high PASI
at the time of switching to the second biologic therapy and
concomitantly using cyclosporine with the second biologic
therapy.
Comparisons with existing literature
Consistent with some, but not all, previous studies, we found
that drug survival rates for the first and second courses of
biologic therapies were comparable (Menting et al., 2014;
van den Reek et al., 2014b). However, compared with
those studies, our research has important strengths: our
sample size was much larger, thereby giving the study more
power for the investigation of comparative second-line bio-
logic survival, and we included patients from multiple
dermatology centers, thus ensuring high external validity.
Our finding that ustekinumab had better drug survival rate
compared with TNFIs among patients who switched to
second-line biologic therapies is in line with results reported
by Menter et al. (2016). However, in contrast to our findings,
Gniadecki et al. (2015), using the Danish National Psoriasis
Biologic Safety Registry Data, reported that the survival of
ustekinumab was equal to that of adalimumab but was su-
perior to that of etanercept among patients previously
exposed to biologic therapies. However, the smaller sample
size of this earlier study (only 576 patients) is likely to have
limited its power to investigate comparative biologic therapy
survival. Furthermore, Gniadecki et al. (2015) did not adjust
for factors that could influence second-line biologic drug
survival. Such factors include patients’ demographic and
disease characteristics; the presence of PsA and other
comorbidities; the concomitant prescription of methotrexate
and cyclosporine; and reason for discontinuation of the first
biologic therapy, which we were able to take account of in
this study.
Factors associated with biologic survival
Discontinuation of second-line biologic therapies was
associated with a range of factors, including choice of
biologic therapy, patient demographic characteristics, andwww.jidonline.org 779
Table 3. Univariate and multivariate Cox proportional hazard analyses for drug discontinuation, presented by
reason for discontinuation from second-line biologic therapy
Variable
Univariate and Multivariate Cox Proportional Hazard Analysis for Drug Discontinuation
Overall Discontinuation
Discontinuation due to
Ineffectiveness
Discontinuation due to
Adverse Events
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Demographics
Age1 0.97 (0.90e1.04) 0.95 (0.87e1.04) 1.01 (0.91e1.11) 0.97 (0.86e1.10) 1.01 (0.87e1.18) 1.05 (0.88e1.26)
Female 1.38 (1.15e1.66)2 1.31 (1.08e1.60) 1.34 (1.05e1.72) 1.22 (0.94e1.59) 1.55 (1.05e2.30) 1.53 (1.01e2.32)
Obesity status3
Obese (BMI  30 kg/m2) 1.26 (0.99e1.61) 1.22 (0.94e1.58) 1.35 (0.96e1.92) 1.29 (0.90e1.86) 0.94 (0.55e1.61) 0.89 (0.51e1.55)
Smoking status4
Ex-smoker 0.84 (0.65e1.08) 0.85 (0.66e1.10) 0.93 (0.66e1.30) 0.93 (0.66e1.32) 0.81 (0.46e1.44) 0.84 (0.46e1.51)
Current smoker 0.96 (0.75e1.23) 0.95 (0.73e1.23) 0.99 (0.70e1.39) 0.97 (0.68e1.38) 0.90 (0.52e1.54) 0.87 (0.50e1.54)
Comorbidities5
Psoriatic arthritis 1.03 (0.83e1.28) 0.86 (0.68e1.09) 1.16 (0.88e1.55) 0.92 (0.68e1.25) 0.91 (0.56e1.47) 0.79 (0.47e1.32)
1e2 comorbidities 1.01 (0.81e1.26) 0.97 (0.77e1.24) 1.02 (0.76e1.39) 0.94 (0.68e1.30) 1.11 (0.68e1.81) 1.04 (0.62e1.77)
3e4 comorbidities 1.35 (1.03e1.77) 1.46 (1.07e1.98) 1.43 (0.99e2.06) 1.40 (0.93e2.11) 1.74 (0.98e3.08) 1.95 (1.02e3.73)
5 comorbidities 1.58 (1.08e2.32) 1.56 (1.02e2.39) 1.58 (0.94e2.66) 1.19 (0.66e2.13) 1.37 (0.56e3.36) 1.52 (0.57e4.06)
Disease
Disease duration1 0.95 (0.88e1.03) 0.95 (0.87e1.03) 0.99 (0.90e1.10) 0.99 (0.88e1.12) 0.87 (0.73e1.03) 0.79 (0.66e0.95)
PASI 1.01 (0.99e1.03) 1.02 (1.01e1.04) 1.02 (0.99e1.03) 1.02 (0.99e1.04) 1.00 (0.97e1.03) 1.02 (0.98e1.06)
DLQI 0.99 (0.97e1.01) 0.98 (0.96e1.00) 1.00 (0.98e1.02) 0.99 (0.97e1.02) 0.99 (0.96e1.03) 0.98 (0.94e1.03)
Concomitant6 methotrexate 1.23 (0.94e1.62) 1.01 (0.76e1.35) 1.66 (1.19e2.31) 1.33 (0.93e1.90) 0.34 (0.12e0.91) 0.29 (0.11e0.81)
Concomitant6 cyclosporine 1.74 (1.17e2.58) 1.55 (1.02e2.36) 2.00 (1.20e3.31) 2.17 (1.28e3.68) 1.45 (0.59e3.56) 0.93 (0.34e2.58)
First-line biologic therapy7
Adalimumab 0.82 (0.67e1.00) 1.07 (0.75e1.52) 0.92 (0.70e1.21) 1.18 (0.72e1.95) 0.70 (0.44e1.10) 0.98 (0.45e2.14)
Infliximab 0.97 (0.63e1.50) 1.02 (0.63e1.64) 1.31 (0.77e2.23) 1.54 (0.85e2.79) 0.60 (0.19e1.93) 0.60 (0.17e2.09)
Ustekinumab 1.85 (1.23e2.77) 1.51 (0.97e2.35) 1.87 (1.08e3.25) 1.38 (0.76e2.51) 2.24 (1.02e4.93) 1.66 (0.71e3.87)
Other biologics8 1.10 (0.49e2.49) 0.87 (0.35e2.18) — — 4.26 (1.68e10.80) 4.62 (1.28e16.62)
Second-line biologic therapy9
Etanercept 2.13 (1.63e2.79) 1.87 (1.24e2.83) 2.77 (1.98e3.87) 2.44 (1.40e4.25) 1.99 (1.12e3.52) 1.64 (0.67e4.01)
Ustekinumab 0.50 (0.41e0.62) 0.46 (0.33e0.64) 0.47 (0.35e0.63) 0.41 (0.26e0.64) 0.42 (0.27e0.67) 0.38 (0.18e0.77)
Reason for discontinuing first biologic therapy10
Ineffectiveness — — 1.08 (0.80e1.46) 1.04 (0.69e1.56) — —
Adverse events11 1.27 (0.97e1.66) 1.34 (1.01e1.78) — — 2.09 (1.28e3.41) 2.55 (1.50e4.32)
Other 1.07 (0.80e1.42) 1.09 (0.80e1.47) 0.83 (0.55e1.27) 0.83 (0.48e1.43) 0.97 (0.50e1.89) 0.82 (0.38e1.75)
Drug year12 0.93 (0.88e0.98) 0.98 (0.91e1.04) 0.94 (0.87e1.02) 0.99 (0.91e1.08) 0.90 (0.80e1.02) 0.98 (0.85e1.13)
Abbreviations: BMI, body mass index; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index.
Data presented as hazard ratio (95% confidence interval).
1To evaluate the hazard ratio for every 10-year increase in age and disease duration at the time of switching to the second-line biologic therapy, continuous
variables of age and disease duration were transformed to age and disease duration divided by 10.
2P < 0.05, shown in bold.
3Reference category: nonobese (BMI < 30kg/m2).
4Reference category: never smoker.
5Reference category: no comorbidities (excluding psoriatic arthritis). Includes (according to Medical Dictionary for Regulatory Activities system organ class):
blood and lymphatic system disorders; cardiac disorders; congenital, familial, and genetic disorders; ear and labyrinth disorders; endocrine disorders; eye
disorders; gastrointestinal disorders; general disorders and administration site conditions; hepatobiliary disorders; immune system disorders; infections and
infestations; injury, poisoning, and procedural complications; investigations; metabolism and nutrition disorders; musculoskeletal and connective tissue
disorders; neoplasms benign, malignant, and unspecified; nervous system disorders; pregnancy, puerperium and perinatal conditions; psychiatric disorders;
renal and urinary disorders; reproductive system and breast disorders; respiratory, thoracic and mediastinal disorders; skin and subcutaneous tissue dis-
orders; Social circumstances; surgical and medical procedures; vascular disorders.
6Time-varying covariates.
7Reference category: etanercept.
8Includes efalizumab and clinical trial biologic therapies.
9Reference category: adalimumab.
10Reference category: ineffectiveness.
11For the multivariate analysis examining predictors for withdrawal due to ineffectiveness, adverse events was used as a reference category.
12Drug year (calendar year the second-line biologic therapy was prescribed) is adjusted for in the multivariate analysis.
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Persistence with Second-Line Biologic Therapies for Psoriasisdisease-related factors. We have shown that when compared
with adalimumab, taking etanercept was a predictor for
discontinuation overall and because of ineffectiveness,
whereas taking ustekinumab was a predictor of drug survival.
Possible reasons contributing to the observed higher drug
survival with second-line use of ustekinumab could include
differences in clinical effectiveness (Griffiths et al., 2010;
Reich et al., 2012), speed of onset of action (Nast et al.,
2013), low immunogenicity (Carrascosa et al., 2014), and
nurse-administered injections provided every 12-weeks,
compared with the more frequent self-injection regimens for
other biologic therapies, which may contribute to improved
drug adherence and treatment satisfaction (Goren et al.,
2016; Hsu and Gniadecki, 2016; Schaarschmidt et al., 2015).
Our study also found that patients were more likely to dis-
continue second-line biologic therapy because of an AE if the
first-line biologic therapy was also stopped for the same
reason. However, discontinuation due to lack of effectiveness
of a first biologic therapy did not appear to predict discontin-
uation due to ineffectiveness of a second. Hence, patients and
clinicians should be reassured that ineffectiveness of the first
biologic therapy does not necessarily mean that there would
be a greater likelihood of experiencing ineffectivenesswith the
second biologic therapy, but it is critically important to remain
vigilant for AEs, particularly among those patients who dis-
continued their first biologic therapy because of an AE. To the
best of our knowledge, the magnitude of the effect that the
reason for failing the first-line biologic therapy has on the
clinical outcome in patients with psoriasis receiving a second
biologic therapy has not been previously reported. Hence,
future studies are required to validate our findings. An earlier
study of the rheumatoid arthritis cohort within the British So-
ciety for Rheumatology Biologics Register also found that the
likelihood of recurrent discontinuation due to AE with the
second biologic therapy was increased by more than 2-fold if
the first biologic therapy was discontinued because of an AE
(Hyrich et al., 2007).
Existing data and guidelines for treatment sequencing after
failure of first-line biologic therapies are limited. Our study
found that the drug survival rate of second-line biologic
therapies was comparable to those reported previously for
first-line biologic therapies, thus supporting findings from
previous studies that switching therapies is a viable option
(Leman and Burden, 2012; Norlin et al., 2012). These find-
ings provide valuable data to inform cost-effectiveness
analyses of sequential use of different biologic therapies in
patients with psoriasis, because many existing cost-
effectiveness models are limited by not considering subse-
quent treatment regimens (Mauskopf et al., 2014). Switching
to another class of biologic therapy is also useful, as shown in
our study by the high drug survival rates of second-line
ustekinumab among patients for whom first-line TNFIs
failed. However, we had a very small cohort of 47 patients for
whom first-line ustekinumab failed and who were switched
to second-line TNFIs. Therefore, future studies with a larger
cohort of patients failing first-line ustekinumab will be
required to establish the potential benefits of switching to
second-line TNFIs.
Concomitantly using cyclosporine with the second
biologic therapy was found to predict the likelihood of drugfailure due to ineffectiveness. In contrast, concomitantly
using methotrexate with the second biologic therapy was
associated with lower risk of discontinuing the second
biologic therapy because of AEs. However, these observa-
tions could potentially be attributed to confounding by
indication for use. Combination therapies are likely to be
used in patients who are not responding adequately to
biologic therapy (Cather and Crowley, 2014).
Because the BADBIR was established primarily as a phar-
macovigilance register, there are some limitations to studying
differential drug survival of second-line biologic therapies
that should be considered when interpreting our findings.
First, information on patients’ adherence to treatment was not
available. Furthermore, the influence of dose escalation on
differential biologic drug survival was not assessed. However,
we have shown previously that patients in the BADBIR
routinely receive the recommended dosing regimen of
biologic therapies but that concomitant treatment with other
systemic therapies occurs commonly (Iskandar et al., 2017a).
One particular challenge that we faced is that patients’
demographic characteristics were not re-recorded in the
BADBIR at the time of switch from one biologic therapy to
another. As a consequence, demographic characteristics
were determined from the patients’ records at the time of
registration with the BADBIR. This included data on smoking
status and comorbidities. It is possible that some patients may
have developed new comorbidities or changed smoking
status during the time when they were receiving their first
biologic therapy. An inherent limitation in any observational
study is nonrandomization, which may introduce selection
bias, and although this is partially negated by adjustment for
clinically relevant covariates, the presence of other unmea-
sured confounders, such as the severity of PsA and its
response to treatment, as well as the intention behind
concomitant medication, cannot be determined. In the
future, it will be important to examine the comparative drug
survival of the recently approved anti-IL-17 biologic therapies
(secukinumab and ixekizumab), and as longer-term follow-
up of patients permits, then additional insights into drug
survival with third-line and subsequent courses of biologic
therapies could also be explored.
SUMMARY
This large prospective cohort study provides insights into the
differential drug survival of second-line biologic therapies in
routine clinical practice. We found that 77% of patients who
were switched to a second biologic therapy continued to
receive the new treatment for at least 12 months. This shows
clearly that patients experiencing treatment failure with one
biologic therapy can benefit from switching to another.
However, second-line discontinuation due to AEs was more
common among those who discontinued first-line treatment
because of AEs. The results of this study should support
clinical decision making when choosing second-line biologic
therapy for patients with psoriasis.
MATERIALS AND METHODS
The BADBIR, established in September 2007, compares a cohort of
patients with psoriasis receiving biologic therapies versus a similar
cohort receiving conventional systemic therapies. Details about thewww.jidonline.org 781
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782design of the BADBIR and the disease characteristics of its partici-
pants have been published previously (Burden et al., 2012; Iskandar
et al., 2015).
Baseline data and follow-up
Baseline data were collected with patient consent and included
patients’ demographic characteristics and lifestyle information: for
example, smoking; details of type and severity of psoriasis and year
of onset; standardized measures of health status using self-reported
outcome measures (Dermatology Life Quality Index); detailed
information about the patients’ current and previous treatment for
psoriasis; and the patients’ comorbidities, the details of which were
classified using the Medical Dictionary for Regulatory Activities
system (Bousquet et al., 2005).
The BADBIR aimed to follow up with all patients at 6-month in-
tervals for 3 years and then annually thereafter, even if the patient
stopped or switched their therapy. Details of the biologic therapies,
including any change in the therapy, gaps in treatment, start and stop
dates, and reasons for discontinuation were recorded. The PASI and
Dermatology Life Quality Index, along with their dates, were also
documented. Information on any new concomitant systemic thera-
pies for psoriasis and their start and stop dates were also captured.
Details of the AEs were classified using the Medical Dictionary for
Regulatory Activities system.
Study population
Subjects in this study were selected from the April 2016 data cutoff.
All patients with chronic plaque psoriasis who registered with the
BADBIR as biologic-naı¨ve patients; experienced treatment failure
with their first biologic therapy for any reason; and then switched to
second-line treatment with adalimumab, etanercept, or ustekinumab
were eligible for inclusion in this analysis if they had one or more
dermatologist follow-ups (i.e., with follow-up data of 6 months)
after switching to the second biologic therapy, because data on drug
persistence were otherwise not available. Patients who were
switched to a second biologic therapy were subdivided into three
groups based on whether they (i) did not show adequate response to
the first biologic therapy, (ii) had developed an AE while receiving
the first biologic therapy, or (iii) discontinued the first agent because
of other reasons, for example, noncompliance.
Statistical analysis
Drug survival was defined as “the length of time from initiation to
discontinuation of therapy” (Cramer et al., 2008, pp 45). Discon-
tinuation of therapy was defined as any gap in treatment for longer
than 90 days, to disregard temporary treatment discontinuation
during an infection or elective surgery and to take into account the
early UK licensing prescription of etanercept in an intermittent
dosing regimen with gaps of fewer than 90 days (Warren et al.,
2015). The discontinuation date included the earliest date of any
switches to third-line biologic therapy or death while registered on
the BADBIR. This definition is in accordance with other drug survival
studies in psoriasis and psoriatic arthritis (Esposito et al., 2013;
Gniadecki et al., 2011; Saad et al., 2009; van den Reek et al.,
2014a; Warren et al., 2015).
Differences in drug survival between second-line biologic thera-
pies were examined using Kaplan-Meier survival analysis, with
censorship occurring if a patient had not discontinued the biologic
therapy at the last available follow-up date. Reasons for discontin-
uation, classified as due to ineffectiveness, due to AEs, and “other,”
were noted for each biologic agent. Patients were categorized asJournal of Investigative Dermatology (2018), Volume 138having an AE if they either stopped therapy because of an AE or
because of both an AE and ineffectiveness.
An a priori list of covariates was determined to address potential
predictors of discontinuation (as presented in Table 3). Adalimumab
was used as the reference biologic therapy with which the others
were compared. Body mass index, derived from measurements of
height and weight dated within 3 months before switching to the
second biologic therapy, was categorized into a binary obese/non-
obese variable. The baseline (switching-time) age and disease
duration of the patients were calculated from patients’ ages recorded
in their baseline questionnaires and the time of switching.
Switching-time PASI and Dermatology Life Quality Index were
identified if they were dated within 3 months before switching.
Other demographic characteristics (that would not change by time)
were obtained from the patients’ baseline forms and included sex
and age of disease onset. Comorbidity with PsA was collected both
at registration and follow-up, whereas other comorbidities and the
patients’ smoking status were collected only at the time of registra-
tion. Concomitant methotrexate and cyclosporine were analyzed as
time-varying covariates throughout the period of follow-up. The year
of second biologic course prescription was included for adjustment
to account for the fact that the available treatment options have
changed over time.
Univariable and multivariable Cox proportional hazard models
were used to identify factors associated with the second biologic
course discontinuation. The proportional hazard assumption was
tested formally using Schoenfeld residuals. Separate models were
developed to analyze overall discontinuation, discontinuation due
to ineffectiveness, and discontinuation due to AEs. In addition to
determining the relationship between the reasons for stopping the
first biologic therapy and the reasons for stopping the second bio-
logic therapy, we undertook separate analyses stratified according to
the reason for stopping the first biologic course.
To account for missing data, the details of which are listed in
Supplementary Table S6 online, we generated 80 imputed datasets.
In each dataset, missing values were replaced by values randomly
selected from the expected distribution of that variable based on the
measured and imputed values of all variables for that individual. This
approach enables all subjects to be used in the analysis, avoiding the
selection bias that would be likely if only subjects with complete
data were analyzed (Bodner, 2008). In general, increasing the
number of imputations reduces the width of any CIs, but there is a
law of diminishing returns. We chose to generate 80 imputed
datasets, because this number resulted in a relative efficiency for all
parameters of 99% (i.e., we could reduce the width of the CIs by
only 1% by increasing the number of imputations indefinitely).
Sensitivity analyses were performed to investigate the differential
drug survival with second-line biologic therapies stratified by the
first-line biologic therapy the patient was switched from (see
Supplementary Figure S2 and Supplementary Tables S3, S4, and S5).
Analyses were performed using STATA version 14.0 (Stata Corp,
College Station, TX).
Ethical approval
The BADBIR was approved in March 2007 by NHS Research
Ethics Committee North West England, reference 07/MRE08/9. All
subjects gave written, informed consent for their participation in the
registry.
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